Paricalcitol does not improve glucose metabolism in patients with stage 3-4 chronic kidney disease

Kidney International

Volumn 83, Issue 2, 2013, Pages 323-330

  De Boer, Ian H ^a,b   Sachs, Michael ^a   Hoofnagle, Andrew N ^b   Utzschneider, Kristina M ^a   Kahn, Steven E ^a   Kestenbaum, Bryan ^a,b   Himmelfarb, Jonathan ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

chronic kidney disease; clinical trial; insulin resistance; metabolism; vitamin D

Indexed keywords

24,25 DIHYDROXYVITAMIN D; 25 HYDROXYVITAMIN D; BIOLOGICAL MARKER; CALCITRIOL; FATTY ACID; FIBROBLAST GROWTH FACTOR 23; GLUCOSE; ISOPROSTANE DERIVATIVE; PARATHYROID HORMONE; PARICALCITOL; PLACEBO;

AGED; ARTICLE; BRADYCARDIA; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; COMMON COLD; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSSOVER PROCEDURE; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DYSPNEA; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GOUT; HEART PALPITATION; HUMAN; HYPERTENSION; INSULIN RESPONSE; INSULIN SENSITIVITY; LOW BACK PAIN; MALE; MUSCLE CRAMP; PARATHYROID HORMONE BLOOD LEVEL; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; VERTIGO; VITAMIN D METABOLISM;

EID: 84873407197     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2012.311     Document Type: Article

References (52)

1. Li YC. Renoprotective effects of vitamin D analogs. Kidney Int 2010; 78: 134-139.
2. Dusso AS, Tokumoto M. Defective renal maintenance of the vitamin D endocrine system impairs vitamin D renoprotection: a downward spiral in kidney disease. Kidney Int 2011; 79: 715-729.
3. Melamed ML, Thadhani RI. Vitamin D therapy in chronic kidney disease and end stage renal disease. Clin J Am Soc Nephrol 2012; 7: 358-365.
4. de Boer IH. Vitamin D and glucose metabolism in chronic kidney disease. Curr Opin Nephrol Hypertens 2008; 17: 566-572.
5. Pham H, Utzschneider KM, de Boer IH. Measurement of insulin resistance in chronic kidney disease. Curr Opin Nephrol Hypertens 2011; 20: 640-646.
6. DeFronzo RA, Alvestrand A, Smith D et al. Insulin resistance in uremia. J Clin Invest 1981; 67: 563-568.
7. Fliser D, Pacini G, Engelleiter R et al. Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int 1998; 53: 1343-1347.
8. Sechi LA, Catena C, Zingaro L et al. Abnormalities of glucose metabolism in patients with early renal failure. Diabetes 2002; 51: 1226-1232.
9. Nerpin E, Riserus U, Ingelsson E et al. Insulin sensitivity measured with euglycemic clamp is independently associated with glomerular filtration rate in a community-based cohort. Diabetes Care 2008; 31: 1550-1555.
10. Dogra G, Irish A, Chan D et al. Insulin resistance, inflammation, and blood pressure determine vascular dysfunction in CKD. Am J Kidney Dis 2006; 48: 926-934.
11. Maestro B, Campion J, Davila N et al. Stimulation by 1, 25-dihydroxyvitamin D3 of insulin receptor expression and insulin responsiveness for glucose transport in U-937 human promonocytic cells. Endocrine J 2000; 47: 383-391.
12. Bourlon PM, Faure-Dussert A, Billaudel B. Modulatory role of 1, 25 dihydroxyvitamin D3 on pancreatic islet insulin release via the cyclic AMP pathway in the rat. Br J Pharmacol 1997; 121: 751-758.
13. Quesada JM, Martin-Malo A, Santiago J et al. Effect of calcitriol on insulin secretion in uraemia. Nephrol Dial Transplant 1990; 5: 1013-1017.
14. Mak RH. Intravenous 1, 25 dihydroxycholecalciferol corrects glucose intolerance in hemodialysis patients. Kidney Int 1992; 41: 1049-1054.
15. Mak RH. Amelioration of hypertension and insulin resistance by 1, 25-dihydroxycholecalciferol in hemodialysis patients. Pediatr Nephrol 1992; 6: 345-348.
16. Allegra V, Luisetto G, Mengozzi G et al. Glucose-induced insulin secretion in uremia: role of 1 alpha, 25(HO)2-vitamin D3. Nephron 1994; 68: 41-47.
17. Lin SH, Lin YF, Lu KC et al. Effects of intravenous calcitriol on lipid profiles and glucose tolerance in uraemic patients with secondary hyperparathyroidism. Clin Sci 1994; 87: 533-538.
18. Kautzky-Willer A, Pacini G, Barnas U et al. Intravenous calcitriol normalizes insulin sensitivity in uremic patients. Kidney Int 1995; 47: 200-206.
19. Mak RH. 1, 25-Dihydroxyvitamin D3 corrects insulin and lipid abnormalities in uremia. Kidney Int 1998; 53: 1353-1357.
20. Khajehdehi P, Taheri S. Effect of oral calcitriol pulse therapy on the lipid, calcium, and glucose homeostasis of hemodialysis-patients: its safety in a combination with oral calcium carbonate. J Ren Nutr 2003; 13: 78-83.
21. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54: 1615-1625.
22. Ramos LF, Shintani A, Ikizler TA et al. Oxidative stress and inflammation are associated with adiposity in moderate to severe CKD. J Am Soc Nephrol 2008; 19: 593-599.
23. Finch JL, Suarez EB, Husain K et al. Effect of combining an ACE inhibitor and a VDR activator on glomerulosclerosis, proteinuria, and renal oxidative stress in uremic rats. Am J Physiol Renal Physiol 2012; 302: F141-F149.
24. Dong J, Wong SL, Lau CW et al. Calcitriol protects renovascular function in hypertension by down-regulating angiotensin II type 1 receptors and reducing oxidative stress. Eur Heart J 2012; e-pub ahead of print 19 January 2012.
25. Coyne D, Acharya M, Qiu P et al. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis 2006; 47: 263-276.
26. Sergeev IN, Rhoten WB. 1, 25-Dihydroxyvitamin D3 evokes oscillations of intracellular calcium in a pancreatic beta-cell line. Endocrinology 1995; 136: 2852-2861.
27. Hung A, Sundell MB, Plotnikova NE et al. Active vitamin D3 administration and insulin resistance in chronic hemodialysis patients. Abstract presented at the American Society of Nephrology Kidney Week, November 20, 2010, Denver, CO.
28. Morrow JD. Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler Thromb Vasc Biol 2005; 25: 279-286.
29. de Zeeuw D, Agarwal R, Amdahl M et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010; 376: 1543-1551.
30. Thadhani R, Appelbaum E, Pritchett Y et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 2012; 307: 674-684.
31. Kolek OI, Hines ER, Jones MD et al. 1alpha, 25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am J Physiol Gastrointest Liver Physiol 2005; 289: G1036-G1042.
32. Saito H, Maeda A, Ohtomo S et al. Circulating FGF-23 is regulated by 1alpha, 25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 2005; 280: 2543-2549.
33. Finch JL, Tokumoto M, Nakamura H et al. Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease. Am J Physiol Renal Physiol 2010; 298: F1315-F1322.
34. Wesseling-Perry K, Pereira RC, Sahney S et al. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney Int 2011; 79: 112-119.
35. Hansen D, Rasmussen K, Pedersen SM et al. Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol. Nephrol Dial Transplant 2012; 27: 2263-2269.
36. Liu S, Tang W, Zhou J et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 2006; 17: 1305-1315.
37. Kawata T, Imanishi Y, Kobayashi K et al. Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol 2007; 18: 2683-2688.
38. Lavi-Moshayoff V, Wasserman G, Meir T et al. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol 2010; 299: F882-F889.
39. Bosworth CR, Levin G, Robinson-Cohen C et al. The serum 24, 25-dihydroxyvitamin D concentration, a marker of vitamin D catabolism, is reduced in chronic kidney disease. Kidney Int 2012; e-pub ahead of print 30 May 2012.
40. Hasegawa H, Nagano N, Urakawa I et al. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int 2010; 78: 975-980.
41. Ravani P, Malberti F, Tripepi G et al. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int 2009; 75: 88-95.
42. de Boer IH, Katz R, Chonchol M et al. Serum 25-hydroxyvitamin D and change in estimated glomerular filtration rate. Clin J Am Soc Nephrol 2011; 6: 2141-2149.
43. Wolf M, Shah A, Gutierrez O et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007; 72: 1004-1013.
44. Shoben AB, Rudser KD, de Boer IH et al. Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol 2008; 19: 1613-1619.
45. Kovesdy CP, Ahmadzadeh S, Anderson JE et al. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 2008; 168: 397-403.
46. Teng M, Wolf M, Ofsthun MN et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115-1125.
47. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22: 1462-1470.
48. Utzschneider KM, Prigeon RL, Tong J et al. Within-subject variability of measures of beta cell function derived from a 2h OGTT: implications for research studies. Diabetologia 2007; 50: 2516-2525.
49. Strathmann FG, Laha TJ, Hoofnagle AN. Quantification of 1alpha, 25-dihydroxy vitamin D by immunoextraction and liquid chromatography-tandem mass spectrometry. Clin Chem 2011; 57: 1279-1285.
50. Rubin DB. Multiple Imputation for Nonresponse in Surveys. J. Wiley & Sons: New York, 1987.
51. Solomon TP, Blannin AK. Effects of short-term cinnamon ingestion on in vivo glucose tolerance. Diabetes Obes Metab 2007; 9: 895-901.
52. Herman GA, Bergman A, Stevens C et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006; 91: 4612-4619.